Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-140711

Published: 2020

Journal Articles

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 581.

https://doi.org/10.1182/blood-2019-127717

Published: 2019

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Blood (2019) 134 (Supplement_1): 4580.

https://doi.org/10.1182/blood-2019-129880

Published: 2019

Journal Articles

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Blood (2019) 134 (Supplement_1): 1852.

https://doi.org/10.1182/blood-2019-128655

Published: 2019

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2019) 134 (Supplement_1): 781.

https://doi.org/10.1182/blood-2019-125204

Published: 2019

Journal Articles

VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data

Alejandro Medina, Cristina Jiménez, PhD, Maria E Sarasquete, PhD, Noemi Puig, MD PhD, Ana Balanzategui, Miguel Alcoceba, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Garcia-Alvarez, B.Sc., Isabel Prieto-Conde, PhD, Carmen Chillon, PhD, Enrique M. Ocio, MD, Norma C. Gutierrez, MD PhD, Maria-Victoria Mateos, MD PhD, Joaquin Martínez-López, MD PhD, Juan Jose Lahuerta, MD PhD, Jesús F San-Miguel, MD, Marcos González, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 4446.

https://doi.org/10.1182/blood-2018-99-114627

Published: 2018

Journal Articles

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Blood (2018) 132 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2018-99-117431

Published: 2018

Journal Articles

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Miguel Alcoceba, PhD, Maria Garcia-Alvarez, B.Sc., Anna Puiggros, PhD, Luis Espinosa-Hevia, PhD, Andrea Gómez-Llonín, B.Sc., Almudena Navarro, MD, Jose Maria Bastida, MD PhD, Norma C. Gutierrez, MD PhD, Jose A. Garcia-Marco, MD PhD, Blanca Espinet, PhD, Ramón García-Sanz, MD PhD, Marcos González, MD PhD

Blood (2018) 132 (Supplement 1): 1851.

https://doi.org/10.1182/blood-2018-99-114995

Published: 2018

Journal Articles

Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment

Esperanza M Algarín, MSc, Andrea Díaz-Tejedor, Pedro Mogollón, Susana Hernández-García, Luis Corchete, Laura San-Segundo, Montserrat Martín-Sánchez, Lorena González-Méndez, Marie Schoumacher, Sébastien Banquet, Laurence Kraus-Berthier, Ioana Kloos, Ensar Halilovic, Heiko Maacke, Norma C. Gutierrez, MD PhD, Maria-Victoria Mateos, MD PhD, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio, MD

Blood (2018) 132 (Supplement 1): 954.

https://doi.org/10.1182/blood-2018-99-116075

Published: 2018

Journal Articles

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Blood (2018) 132 (Supplement 1): 126.

https://doi.org/10.1182/blood-2018-99-111924

Published: 2018

Journal Articles

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Blood (2018) 132 (Supplement 1): 112.

https://doi.org/10.1182/blood-2018-99-113312

Published: 2018

Journal Articles

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 474.

https://doi.org/10.1182/blood-2018-99-115050

Published: 2018

Journal Articles

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2018) 132 (Supplement 1): 2142.

https://doi.org/10.1182/blood-2018-99-112656

Published: 2018

Journal Articles

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

Blood (2016) 128 (22): 194.

https://doi.org/10.1182/blood.V128.22.194.194

Published: 2016

Journal Articles

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

Juan-Manuel Sancho, Francisco Gual, Rubén Fernández-Alvarez, Esther González-García, MD, Carlos Grande, MD PhD, Carmen Jiménez-López, Norma C Gutierrez, MD PhD, María-José Peñarrubia, Ana Batlle, Eva González-Barca, MD PhD, Jose-Maria Guinea-de-Castro, Eva Gimeno, MD PhD, Francisco-Javier Peñalver, MD, Miguel A Fuertes, Jorge Gayoso, MD, José-Ángel Hernández-Rivas, José-María Moraleda, MD PhD, Lluis Virgili, Alejandro Martín, MD PhD

Blood (2016) 128 (22): 5387.

https://doi.org/10.1182/blood.V128.22.5387.5387

Published: 2016

Journal Articles

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Blood (2016) 128 (22): 5688.

https://doi.org/10.1182/blood.V128.22.5688.5688

Published: 2016

Journal Articles

Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity

Teresa Paíno, Bruno Paiva, José M Sayagués, Ines Mota, Tiago Carvalheiro, Luis A Corchete, Norma C Gutiérrez, MD, PhD, Irene Aires-Mejia, Maria Luz Sanchez, Paloma Barcena, Enrique M. Ocio, Albert Oriol, MD, Miguel T Hernandez, Maria Asunción Echeveste, Artur Paiva, PhD, Joan Blade, MD, Alberto Orfao, Maria Victoria Mateos, MD, PhD, Jesus F San Miguel, MD, PhD

Blood (2013) 122 (21): 531.

https://doi.org/10.1182/blood.V122.21.531.531

Published: 2013

Journal Articles

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Fermin M. Sanchez-Guijo, MD, PhD, Eva Lumbreras, BSc, Patricia Morais, BSc, Juan-Luis Garcia, PhD, Norma C. Gutierrez, MD, PhD, J.F. San Miguel, MD, PhD, Consuelo del Canizo, MD, PhD, Jesus M. Hernandez-Rivas, MD, PhD

Blood (2007) 110 (11): 2947.

https://doi.org/10.1182/blood.V110.11.2947.2947

Published: 2007

Journal Articles

Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenström’s Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.

Norma C. Gutierrez, MD, PhD, Enrique M. Ocio, MD, PhD, Patricia Maiso, BSc, Encarna Ferminan, PhD, Manuel Delgado, BSc, Ricardo Lopez-Perez, PhD, Maria L. Sanchez, BSc, Maria J. Arcos, MD, Maria J. Moro, MD, Jose M. Hernandez, MD, Alberto Orfao, MD, PhD, Ramon Garcia-Sanz, MD, PhD, Jesus M. Hernandez, MD, PhD, Jesus F. San Miguel, MD, PhD

Blood (2005) 106 (11): 503.

https://doi.org/10.1182/blood.V106.11.503.503

Published: 2005

NARROW

Clinical Validation of a NGS Capture Panel to Identify Mutations, Copy Number Variations and Translocations in Patients with Multiple Myeloma

Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data

Biomarkers for Predicting Long-Term Disease Control in Transplant-Ineligible Multiple Myeloma Patients: The Presence of an MGUS- like Signature Is the Most Relevant Predictor

Design of a NGS Platform for the Integrated Analysis of Genetic Mutations, Copy Number Alteration and Somatic Hypermutation of IGHV in CLL

Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Clinical Significance and Transcriptional Profiling of Persistent Minimal Residual Disease (MRD) in Multiple Myeloma (MM) Patients with Standard-Risk (SR) and High-Risk (HR) Cytogenetics

Immunofixation (IF) in Urine Is Really Necessary to Define Complete Remission in Multiple Myeloma (MM)? a Subanalysis from the Pethema/GEM2012MENOS65 Phase III Clinical Trial

Curativestategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmrf CoMMpass Study

R-COMP Vs. R-CHOP As First-Line Treatment for De Novo Diffuse Large B-Cell Lymphoma in Patients Older Than 60 Years: Preliminary Results from a Prospective Randomized Phase 2 Study from the Spanish Group Geltamo

The Poor Prognosis of High Cytogenetics Abnormalities in Elderly Patients Might be Overcome with an Optimized Total Therapy Approach Including Proteasome Inhibitors, Imid's Compounds and Alkylators

Phenotypic Identification Of Subclones In Multiple Myeloma With Different Genomic Profile, Clonogenic Potential and Drug Sensitivity

Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.

Gene Expression Profiling of B-Lymphocyte and Plasma Cell Populations from Waldenström’s Macroglobulinemia. Comparison with Expression Patterns of the Same Cell-Counterparts from Other B-Cell Neoplasms.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only